Beginning July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge Program. The purpose of this program is to help eligible Medicare Part D beneficiaries access certain GLP-1 weight-loss medications at a reduced cost while CMS evaluates future obesity treatment initiatives.

Eligibility will be determined by CMS and may require:

• Active Medicare Part D coverage
• A prescription from a healthcare provider for an eligible medication
• Meeting CMS prior authorization requirements

Medications expected to be included in the program are:

• Foundayo
• Wegovy
• Zepbound KwikPen

*Ozempic and Mounjaro (tirzepatide) are not currently included in the program.

For the latest information and eligibility requirements, visit the CMS Medicare GLP-1 Bridge Program page.

Questions about how this may affect your Medicare coverage? Feel free to reach out to Ettie, Ashley, or Taunya at 385-234-6754. We’re happy to help you understand your options.